ArticlePDF Available

Mood and cognitive effects of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'): Week-end 'high' followed by mid-week low

Authors:

Abstract and Figures

Recreational use of +/-3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') is widespread. The present study aimed to examine both the acute and residual effects of this drug on users' mood and cognitive function. A parallel group design was used to compare 12 participants who reported having taken MDMA with 12 participants who reported having consumed only alcohol, on the relevant night (day 1). These same participants were then re-assessed the following day (day 2) and again mid-week (day 5). Acute effects of MDMA broadly replicated previous findings. MDMA users rated elevated mood on day 1 but significantly low mood on day 5, at which point some participants scored within the range for clinical depression. In contrast, the alcohol group showed less pronounced changes, which followed a U-shaped curve over days with the lowest point being day 2. The MDMA group also showed significant impairments on an attentional/working memory task, compared with alcohol users. Weekend use of MDMA may lead to depressed mood mid-week. Possible mechanisms underlying the findings are discussed in terms of temporary depletion of serotonin, serotonergic neurotoxity and psychological aspects of mood change.
Content may be subject to copyright.
Add iction (1 997 ) 92 (7 ), 82 831
R E SE A R C H R E P O R T
M ood an d cog niti ve effe cts of
63,4 -m e th yl en edio xym etham p he ta m in e
(M D M A , `e csta sy ’ ): w ee k- en d `h igh ’ fo llo w ed
b y m id -w ee k l ow
H. VALER IE C URRAN & ROSS A . T RAVILL
D ep ar tm en t of P sy ch ol ogy , U n iv er sity Co lle ge Lo ndo n , U K
Abstract
A im s . Re cr eat io na l use of 63 ,4 -m e thy le ne di ox ym e th am p h eta m in e ( M D M A , `e cs ta sy ’ ) i s w id esp r ea d. T h e
pr es en t s tud y ai m ed to e xa m in e both th e acu te an d resi du a l ef fe cts of this dr ug on use rs ’ m ood a nd cog ni tiv e
fu nc tio n . Design and participants. A p ar allel g rou p d esign wa s us ed to co mpa re 1 2 p ar tici pants w ho
re po rte d ha vi ng taken M DMA w ith 1 2 p ar tici pa nt s w ho reported h av ing consu m ed o nl y alcohol, on t he
re lev an t ni gh t (day 1 ). T hese sam e pa rt ici pa nts w er e the n re -a ss ess ed th e follo w ing da y ( da y 2) a nd a ga in
mid-week (day 5). Fi nd in g s. A c ute ef fec ts of MD M A b roa d ly rep lic at ed pr ev iou s ® ndin gs . M DM A use rs
ra ted elev ate d m oo d on da y 1 but si gni ® ca ntly lo w m oo d on day 5 , at w hic h p oin t som e p ar tic ip an ts sc or ed
w ith in th e ra ng e for cli ni ca l dep r ess io n. In co nt ra st , the al co ho l gro up s ho we d les s pr on ou n ced c ha n ges ,
w hi ch f oll ow e d a U- sh ap ed cu rv e o ve r da y s w ith th e lo we st po int bei ng da y 2. T h e M D M A gr oup a lso
sh ow ed sign i® cant imp ai rm en ts on a n a tt ent ion a l /w or ki ng mem o ry task , co m p ar ed with alco h ol u se rs .
Con c lu sio n s. W e ek end use of M DM A m ay l ead to d epr ess ed m oo d m id- w eek . Po ssi ble m ec ha nis ms
un de rly i ng t he ® nd ing s a re d is cu ss ed i n te rm s o f te m po ra ry d ep le tio n o f se rot on in , se ro to ne rg ic n eu rot o xi ty a nd
ps ych o log ical a sp ects of m o od c ha ng e.
In tr od u ctio n
Desp ite legislative ac tion and m ed ia c am pa igns,
rec reati onal us e of ( 6) 3,4-m ethylene-
di ox yme th am ph eta mi ne (M D M A, `Ec sta sy’ ) re -
main s wide sp rea d (Perou tk a, 1987 ; St eel e,
McCann & R icaurte, 199 4). The effec ts o f
MDM A o n m oo d and cognition have rec eiv ed
rel ati vely little att ention fro m researchers. Th is is
pa rtl y be cau se c on trolle d la boratory stu die s with
hu ma ns ar e generally precluded for leg al and
eth ic al re as on s and s o stud ies on h um ans a re
res tri cted to recreational u ser s. N eu rotox ic e f-
fec ts of M DM A h av e bee n dem on st rat ed in ro-
dents and non-human primates, but it is not
cle ar whethe r similar eff ect s oc cu r in hum an s
(Rica urte et a l., 1992; G reen, Cr os s & G oo dw in,
199 5) . U s e o f M D M A has be en ass oc iate d w it h
sle ep d is turbance (A lle n, M cCann & R ic aurte,
199 3) and the literat ure con tains a ra nge o f case
rep orts of ind ividuals d evelo pin g psyc hiatric
pro bl em s foll ow ing M DM A u se (cf . M c Gu ire ,
Cope & Fahy, 1994; Steele et al., 199 4).
Co rre sp ond en ce: Dr H. V a ler ie Cu rra n, C lin ica l Hea lth P sycho log y, U niv er sity C ol leg e Lo nd on , Gow er S tre et,
Lo nd on W C 1E 6 BT , U K. T el : 144 (0) 1 71 38 0 78 97; f ax : 14 4 (0) 171 916 1989; e-m ai l: v.cu rran@ uc l.a c.u k
Sub m itted 19th J uly 19 96; i nit ial rev ie w com ple ted 15th O cto be r 1996; ® nal ver sio n acce pte d 20th Ja nu ar y 1997.
0965± 2140 /97/070 821± 11 $9.50 ÓSo cie ty f or th e S tud y o f Ad di ction t o Alcohol and Oth er D ru gs
Ca rf ax P ub lish in g Com pa ny
822 H . V. C urr an & R. A. Tr av ill
Although d op am ine-relea sing e ffec ts of MDM A
ha ve b een demonstrated (e .g. Yama moto &
Sp an os , 19 88) , i ts sero tonergic effects ap pear
most pro mi ne nt (Steele et a l., 1987; S chmidt,
19 87) . D cits in s ero to nin in hum an s could b e
associated with both detriments in cognitive
fun ct ion and dis tu rbed mo od r egu la tio n (K rys ta l
& Pr ice , 1992; St eel e t al., 199 4; C u rran &
Ko pelman , 19 96) .
Of the s tudie s of the effect s o f M D MA on
mood, m os t ha ve a ss es sed o nly acute eff ect s.
Only o ne study wa s fo un d which objectively
as ses sed e ffec ts o n co gnitiv e function, and this
in vo lved chron ic u se rs of M D MA. T wo studies
of ac ut e M D M A effe ct s w er e con du ct ed pri or
to go ve rnm enta l restrict ion s. D ow n ing (1986)
as ses sed e ffec ts o f M D M A ( av era ge do se 2 .5
mg/k g) in 21 volun teers w ith pre vious MDM A
ex per ience. Se lf-r ep ort measures o f acute effects
in clu ded eu ph oria, in creased p hysic al an d
em ot ional e nergy , heightened sensual aware ne ss
an d de creas ed a ppeti te. S om e sh ow ed gait ins ta -
bil ity , tri sm us an d in creased deep te nd on
re¯ e ct ion . O nly thre e h ad a ny a pp ar ent co gn itive
effe ct s as indexed by prob lem s p erfor ming m ath-
em at ica l ca lcu lat ions. Sim il ar m ood e ffects we re
rep or ted by Greer & T albot (19 86) in a sum -
mary of 29 cl inical sessions i n whic h M D MA
(in it ial dose ran ge 7 150 mg foll ow ed late r by a
se con d 5 75 m g dose) wa s used as an adju nc t
to psyc hothe rapy. T he re have been two re tro -
sp ect ive stu die s, re ly ing on p articipa nts’ me mor-
ies for prior use of MDM A . Pe ro ut ka , Newma n
& H arris (198 8) as ked stu dents w h o we re rec-
rea tio nal users of MD M A to comple te a qu es -
tio nn aire ab ou t ac ute an d `lin gerin g’
(.24- ho ur ) effe ct s o f M D M A. A g ain , a cu te
effe ct s li ste d in cl ude d a sense of c loseness to
others an d e up ho ria but le ss t ha n 25 % of the
sa mp le r at ed a ny ling eri ng effec ts of M D M A. In
an other retros pec tive s tud y, L ieste r et a l. (1 992)
in ter view ed 20 psy chiatrists wh o h ad use d
MDM A an d t he m o st frequentl y n ote d a cu te
effe ct s we re decreas ed m otivation to p erform
mental or p hy sical tas ks , decreased app etite and
tri sm us . Only a sm all m inority rep or ted any co g-
nitive effe cts of th e drug .
Su ch s tu dies are clearly limited by t he lack o f
ob jectiv e asse ssmen t of cognitiv e effects. In con-
tra st , Krystal & Price (199 2) as se ssed nine indi-
vid ua ls w ho ha d ex te ns ive h istories o f M D MA
us e on a w id e ba ttery of ne urops ycholog ica l
tes ts . Te st result s revea led few clinically
sig ni ® can t co gn itiv e pro bl em s. Howeve r,
co mp ared with no rmati ve d ata the re w as s om e
indic ation o f a m ild to m oderate impairm en t on
bo th imm ed ia te and d ela ye d lo gi cal m em o ry
tes ts fr om t he Weschler M emo ry S ca le. T h ere
wa s no indic ation o f depress ed m o od ( eit he r sel f-
or clin ician-rated) in these nine p eo pl e, alth oug h
it should be no ted th at they ha d n ot t ak en
M DM A f or a n av er age of 66 da ys p rio r to t he
as ses sment.
W ha t is no t kn ow n are t he cog ni tive effe cts of
M DM A fo llo wi ng a sin gl e d os e, or th e pos sib le
res idual effects on cognitio n an d/ or moo d a few
da ys l ate r. L ev els of 5-HT , a cu tely el eva ted by
M DM A , are th en de ple ted fo r an un kn ow n pe-
rio d, such th at m ood a nd co gnition m ay be
affe ct ed fo r some d ay s fol lowin g the u se of
MDM A . As p erhaps the m ajo rity of recreational
M DM A use rs t ak e t he d ru g a t th e w eek en d, but
do not take it a gain u ntil th e follo win g w ee kend,
it is i mp ort ant to as ses s th e d rug ’ s e ffec ts no t
on ly a cutely bu t also residually ov er subseq ue nt
da ys . Th is m a y b e especially imp ortant fo r t he
ma ny M D M A u se rs w ho a re a lso students (Pe r-
outka, 1987) for whom cognitive impairment
ma y a dv ers ely a ffe ct t heir le arnin g.
The present stu dy therefo re aim ed to asses s
bo th t he a cute and r esi du al e ffec ts o f M DMA on
co gnition and m o od in recreation al u sers. G iv en
tha t the illi cit status of th e drug p rec ludes c on -
tro lled laboratory s tu dies, th e present re sea rc h
wa s a e ld stud y, t ak in g place initia lly in a club
set tin g with f oll ow -up as sessm en ts o n sub-
seq ue nt d ays i n ea ch p arti cip ant’ s ho me. Som e
co nt rol for tes ting w as obtai ned in that t he clu b
pro vi ded a qu ie t roo m a wa y from the dan ce a rea
in w hich a ss es sme nt s to ok p lac e. T hi s a rra ng e-
ment was possible as the psychologist assessing
pa rtic ipants had p re vio us ly b een emp loyed a s a
pa rt- tim e disc jockey a t the cl ub . Vo lu nte ers w h o
rep or ted us e of M D M A o n th e S at urd ay n igh t
we re assessed on that ev en ing and th en thes e
sa me p eo ple were fo llo wed- up for repe at assess -
ments the next day and again 4 days later. As a
co mp ariso n group, w e assesse d peop le w ho re-
po rte d u se o f alcohol bu t no illicit dr ug s. Id ea lly ,
the aut ho rs w ou ld h av e us ed a d ru g-free grou p
as a co ntrol for rep eat testing but th ere we re n o
vo lun teers w ho w ere d ru g-free in t he en vi ron-
me nt fro m w hi ch the M DM A u ser s we re r e-
cru ite d. F urther, u se o f drug -fre e volu nteers
fro m a n on -c lub environmen t would have impli-
cat ed m an y non-spec c factors in th e co mpari-
M oo d and co gni tiv e eff ec ts o f MD M A 823
so n. T he alcoho l users w ere sele cted p artly b e-
ca us e co gnitiv e effects o f al co hol a re w ell -
do cu me nt ed (Finnigan & H amm ersley, 1992 ).
Although, so me years ag o, a lcohol an d M D MA
were a ss oci ated with `c lub’ a nd `r ave s ett ing s,
res pe ctively, n ow ad ay s restricti on on `ra ve s’ has
led to mo re o ve rla p of d ru g us e in c lub settings
so t ha t th ere were s uf® c ien t numbers o f vo lun-
tee rs a va ila ble w ho reported taking o nly MDM A
or o nly alc oh ol.
M et ho d
Pa rticipa nt s
Vo lu nte ers were recru ited in a club setting on
su cce ss ive S aturd ay n ig hts o ve r a p eri od of 4
months. T he clu b kin dly prov ided a q uiet roo m
in w hich the s tud y to ok p la ce o n da y 1 (Saturday
night). The s tud y had approval fro m the ins titu-
tio nal ethic al co m mi tte e and a ll p articipa nt s ga ve
writt en, inform ed c on se nt b oth o n t he Saturday
night an d ag ain the fol lo win g day. Recru itm en t
us ed a snowball technique (Solow ij, Hall & Lee,
1992) and volunteers who reported having taken
drugs oth er than MD M A o r alcohol, or a co mbi-
na tio n o f both, were not inclu ded in t he study .
In al l, 2 4 p eop le w h os e ag es r an ged from 20 to
27 years p ar tic ipa ted in the study an d they we re
all test ed o n each of t he t hree o ccasions. Tw el ve
of the sample reported that they had taken
MDM A on da y 1 ( i.e. Sa tu rda y n igh t); 12 re-
po rte d they had take n alcohol b ut no o th er p sy -
ch oa ctiv e d rug s (a pa rt fro m caffein e an d/or
nicot ine ) on d ay 1 . Th ere we re eigh t male s an d
fou r fe male s in each group. Of t he M D M A
gro up, six subjects were stud ents s tud ying fo r a
degre e, s ix w ere in e mplo ym en t (thre e w ith
GC S E a nd three w ith A-level quali® cati on s). O f
the alcohol group, seven were students studying
for a d eg ree , ® ve w ere in emplo ym en t (th ree wi th
GC S E a nd two w ith A -le vel quali ® c at ion s).
Pr oc edu r e
Vo lu nte ers were ta ke n in div idually to t he qui et
st ud y room where wa ter wa s avai lable t o th em
an d th ey w ere ask ed to rea d an inform ati on s hee t
ab out the 5 -d ay s tud y an d to d is cu ss th eir p ar-
tic ip atio n with t he experim enter. Indivi dua ls
who th en w ished to participat e were a sk ed to
giv e written , in forme d con sent. T hey then com-
ple te d th e tasks (question na ires and r at ing scales
described b elo w). Once the t as ks w er e c om -
ple te d, a rra ngem en ts w er e m ad e t o m eet up th e
fol low in g da y in order to c on du ct the d ay 1
tes tin g. Part icipants w ere as ked no t to t ak e an y
fur the r alco ho l or ill ici t su bst an ces be tw ee n d ay
1 an d day 2 testings. The pa rti cipant was then
shown back to the club.
Su bs equen t testing was ca rried o ut in the par-
tic ipa nt s home o n da y 2 (betw een 12 ;00 noon
an d 4.00 p.m.), a nd o n d ay 5 (between th e
ap pro xima te time s of 5 .30 p.m. and 8.30 p .m .).
Th e se tti ng wa s as quiet as p os sib le, gene ra lly a
roo m a wa y fro m d is tra ctio ns such as T V and
ot her peo pl e. O n day 2, partic ipa nt s we re ® rst
as ked if th ey s till wished t o ta ke p ar t in the s tud y
an d if so, to ag ain sign a n in forme d consen t
for m. A fter te st ing on d ay 2 , participan ts w ere
as ked to ® ll in a b rie f questionn aire d eta iling
the ir age, o cc up ation a nd f req uenc y of u se o f a
ran ge of d ifferent drugs . Participan ts ’ r etr os pec-
tiv e reports o f amount of a lco ho l an d other drug s
tak en the p rev io us n ight was a lso reco rd ed . On
da y 5, th e tes ts we re ru n fo r the t hir d tim e in the
sa me o rder us ing t he sam e instruct ion s. Again,
pre ca ution s were tak en to try to keep ea ch te st
the sam e, suc h as asking su bjects not to d rin k or
tak e illeg al s ub stances b etwee n d ay s 2 an d 5 .
As ses sm e nts
Pr os e re ca ll ta sk . This task parallels the para-
gra ph re ca ll ta sk f rom the W es chl er M em o ry
Sc ale u sed by K ry st al & Price (1 992). V ers io ns
us ed w ere f rom the R iv erm ea d B ehavioural
M em or y B at ter y (W i lso n, C o ckb ur n & B ad de-
ley , 19 85 ). Th e expe rim en te r re ad a pros e para -
gra ph alo ud and the participa nt reca lled it aloud
(i) im m ed iat ely and (ii) after a delay ® lled by a ll
ot her a ssess ments (approximate ly 1 2 0 m in utes
lat er) . Re ca ll w as s co red in the standard way
wit h o ne po int b ei ng g iv en for each of the po ss -
ibl e 21 details rec alled p erfectly o r a c lo se s yn -
on ym ; ha lf a poin t for pa rti al reca ll o r pa rti al
sy no nym . O rder o f the th ree ve rsions used were
balanced across subjects and design.
Se ria l se ve ns . T his is a task tap ping concen -
tra tio n an d w or kin g mem ory. T he p ar tic ipa nt is
as ked to s erially subtract a s man y sevens fro m a
giv en thre e-dig it nu mber as th ey c an i n 12 0
sec on ds ( e.g . given 876, t he c orrect res po nses
wo uld beg in 869, 8 62, 855 , 84 ). The nu mber
of correct subtractions and the number of errors
ma de i n th e tim e al lot ted is rec ord ed . Three
824 H . V. C urr an & R. A. Tr av ill
ve rsi ons were used wit h o rder bala nce d a cro ss
su bje cts a nd d esign .
Be ck D ep ression I nv en to ry (Beck et a l. , 19 78) .
This s tanda rd d epr es sio n in vento ry was g ive n at
ea ch te sting p oint.
M oo d ra tin g sc al e. Th is c on sis ts o f 16 v isual
analogue scales each of 100 mm and anchored at
ea ch end w ith co ntras ting descriptors of p res en t
mood (Bond & Lader, 1974 ). S co re o n ea ch
sc ale i s measured in m m from th e le ft a nchor to
th e line m ar ked by th e participant as correspond-
in g to h is/her cu rren t m ood.
Bo di ly sy m pt om s s ca le. T his scale is o f sim ila r
co nstru ction, co ns isting of 14 v isu al a na logue
sc ale s an chore d at o ne e nd b y `no ph ys ical s ym p-
to m’ and at th e ot her b y `p hy sic al sy mp to m
se ver e’ .
Results
A na ly sis
A r epe at ed me as ure s ana lys is o f va ria nce w as
ca rrie d o ut o n al l va ria bles with g rou p (MD M A
ve rsu s al cohol) as a betw een-s ub jects fa cto r and
tes ti ng d ay as a within-s ub jec ts fac tor.
Pa rticipa nt s’ rep or ted drug u se
In t erm s o f fre qu en cy o f us e of d ifferent d ru gs,
th e M D M A gro up rep or ted m ore reg ul ar us e o f
a r an ge o f d rugs w ith alcohol, can na bis , M D MA
an d c oca ine (r esp ec tiv ely ) b ein g the m os t fre -
qu en tly use d. O the r d rugs listed in th e q ue sti on-
na ire i ncluded am ph etam ine, LSD, G HB
(ga m ma -h ydrox ybuty rate), `mu shroo ms and
he roi n bu t few participan ts repo rte d th ey h ad
ever used these, and those that had only rarely.
In t he M D M A g rou p , two peo pl e rep ort ed usi ng
M DM A o nc e a we ek , s ix a pp rox ima te ly on ce p er
mo nth and fou r only occasiona lly. In the alco hol
gro up , t hr ee part ici pan ts sai d th ey to ok MD M A
ap pro xima tel y on ce p er m onth , fou r only
oc cas ion al ly an d ® v e ha d n ev er ta ke n th is d rug.
Re po rts give n o n day 2 o f drug us e th e pre-
vio us e ve nin g co n® r med that 12 p articipa nts be-
lie ved t he y ha d ta ken M D M A bu t se ven
pa rtic ipants said t hey ha d a lso t ak en b etween 1
an d 3 u ni ts (m ean 1 .8 u nits) of a lco hol. F or
mo st , this alcohol use wa s be fo re they arrived at
the club , althoug h fo r tw o p ar tic ipa nt s it w as a t
the club . Th e other 12 participan ts re po rte d no
illi cit d rug u se on day 1 and b etwee n 4 an d 14
un its ( mean 10.8 uni ts) of alco hol o n d ay 1 . T he
am ou nt o f a lc oh ol tak en b y 7 of th e MD M A
us ers w as sm all co mp ared w ith th e `alcoh ol
gro up , al tho ug h it m ay have had a n eff ect . The
gro up s wi ll sti ll be ref erre d t o as `M DM A ’ a nd
`alc oh ol’ . O nl y o ne s ub jec t rep ort ed d rin ki ng
alc oh ol (3 un its) betw een d ays 2 an d 5 ; n on e
sa id th ey ha d taken illic it drug s.
Pr os e re ca ll. T here was a trend (p,0.0 6) for
the M D M A g roup to ha ve l ow er s cores o n im -
me diate recall on all three as se ssment da ys. A
sig ni ® cant m ain effect o f test da y (p,0.001)
wit h n o signi® ca nt interact ion b etween gro up
and day re¯ ected improved performance over
da ys b y bo th g ro up s (T able 1 ). T he pattern of
res ults on de la yed reca ll w as bro ad ly s im ila r: a
tre nd fo r lo we r s co res i n the M D M A gr ou p
(p,0.0 6) a nd a ma in effect of t es t da y
(p,0.0 01) . A dd iti on ally , the int era ct ion o f
gro up with da y s ho we d a s lig ht t ren d (p50.092)
re¯ e cti ng bett er performan ce on d ay 5 by the
alc oh ol grou p.
Se ria l s ev ens. T he n umber o f co rrect s ub trac-
tio ns on t his t as k revea led a sign ca nt g ro up by
days interaction (p,0.05 ) a s we ll a s a m ai n
Table 1. Gro up m ean s (s tand ar d dev iati on s) ov er da ys f or ser ial s even s an d pr ose r ecal l tas ks
M DM A Alc o hol
Da y 1 Da y 2 Da y 5 Da y 1 D ay 2 Da y 5
Ser ial s ev ens : n2.7 (1.9) 14.2 (6.7) 25.1 (7.1) 6.3 (3.4) 26.6 (10.7) 31.1 (11.1)
Serial seven s: e rror 2.3 (2.8) 2.6 (2.9) 2.3 (1.9) 2.8 (1.5) 2.1 (2.4) 1.1 (1.4)
Recall: immediate 1.2 (1.5) 5.9 (2.8) 8 .5 (3.1) 3.5 (2.8) 9.0 (4.4) 10.2 (4.6)
Recall: delayed 1.1 (1.0) 4.0 (1.8) 6.4 (3.7) 2.0 (2.0) 7.5 (3.9) 6.9 (3.3)
0
10
1
Day
MDMA users Alcohol users
Serial seven s: N subtractions
5
15
20
25
30
35
2 5 1 2 5
M oo d and co gni tiv e eff ec ts o f MD M A 825
Fig ur e 1. M ea n n um ber corre ct on the ser ia l seve ns task f or the MD M A an d a lco hol g r oup s on d ay s 1, 2 a nd 5 .
effe ct of b ot h gr ou p (p,0.01) an d da ys
(p,0.0 01 ) ( Fi g. 1) . T he MD M A gro up ma de
few er sub tra cti ons tha n the a lco ho l gro up a t all
as ses sment po ints, b ut these gro up d ifferences
were m o re m arked on day 2 than d ays 1 a nd 5.
There were n o signi® ca nt gr ou p differen ces in
nu mber of errors m ad e.
Be ck D ep res sion Inv entory. Scores on this in -
ventory showed a very signi® cant interaction be-
tw een gro up a nd day of t estin g (p,0.001). A s
se en in F ig. 2, the t wo grou ps o f participan ts h ad
ve ry similar sco res on da y 2. O n day 1, M D M A
us ers scored low er t ha n alcohol u se rs. O n d ay 5,
th is pattern w as reversed su ch th at t he M D M A
us ers s co red a me an o f 11 .75 , whereas alc oh ol
us ers s co res we re s imilar to t he ir in itial ratings
on d ay 1 . Scores of less than 9 on t he B DI are
co nsider ed w ith in th e n orm a l ran ge (Elkin ,
19 94) a nd th os e ab ove 1 6 a s indi cat iv e of clinical
depre ssion (Shapiro et a l., 1994). On day 5 , th e
va ria nce in BD I s co res o f th e M DM A gro up w as
hig he r th an o n t he p rev io us 2 test d ay s, s uch that
so me individ ua ls in thi s gro up were scoring
within th e no rm al ra ng e wh ereas others were
sc ori ng w ith in th e m ild to m od era te c lin ica l
depre ssion range.
M ood r ati ng sc ale. Visual analogue ratings
sh ow ed m ar ke d grou p differen ces ov er the 3 test
days, with 11 of the 16 scales showing signi® cant
group 3test -day inte ractio ns ( Ta ble 2). The
mo st sig ni® can t grou p 3day in terac tio ns
(p,0.0 01) were co nt ented± dis co ntente d;
ha pp y± s ad a nd int ere sted ± bored. Thus, as se en
in T ab le 2, th e M DMA gr ou p on da y 1 w ere
mo re con tented, happ y an d in te res ted than al-
co ho l users . MDMA users be came pro gress ively
mo re d is contented, s ad a nd bo red over the su b-
seq ue nt t est da ys w he rea s alco hol us ers s ho wed a
sli gh t `U-sh ap e’ cu rv e o ve r the 3 d ay s, rating
sli gh tly lo wer m oo d on day 2 c om pare d with
eit he r day 1 o r 5.
Five scales showed group 3d ay interactio ns a t
p,0.0 1. D ro wsin ess (alert ± drow sy ) ra tin gs were
hig h fo r bo th grou ps o n day 2 w ith the ma in
gro up differen ce s temm in g fro m h igh alertnes s
rat ing s by MD M A us ers on da y 1 . R a tin gs of
str on g± f eeb le s ho we d M D M A u ser s r ati ng th em -
sel ve s ver y stro ng o n d ay 1 , an d t hen more feeble
tha n a lco ho l us ers on d ay 2. `M uz zy clear-
hea d ed’ rat in gs a lso s ho we d M DM A us ers a s
mo re c lea r head ed o n d ay 1 b ut rat her more
mu zzy on da y 2 than alc oh ol u ser s. T his pattern
of gro up di ffer en ces ov er d ays was al so s een o n
0
4
1
Day
MDMA users Alcohol users
BDI sc ore
2
6
8
10
12
2 5 1 2 5
826 H . V. C urr an & R. A. Tr av ill
Fig ur e 2. M ea n s cor es on the Be ck Dep res sio n In ven tor y f or the MD M A an d a lcoh ol g ro ups o n da ys 1 , 2 an d 5 .
rat in gs o f `le thargic± en erget ic and `tro ubl ed ±
tra nq ui l’ w ith M DM A us ers ra tin g v ery h igh on
en erg y and tranquillity on d ay 1, b ut l ow er tha n
alc oh ol u se rs o n day 2. A s im ila r pa tte rn w as
ob taine d for sc ale s s ho wing a group 3d ay in te r-
ac tio n which reache d signi® cance at 0.05:
MDM A users rated th em se lves as m ore am i-
ca ble , mo re pro ® cient a nd l ess clums y th an a l-
cohol users on day 1.
Bo dil y S ym pt om s Sc al e. Three scales showed
gro up 3da y in teraction s at the 0.0 01 le vel. Pre-
di cta bl y, M D M A use rs had ve ry hig h `s we ati ng’
sc ore s on ly o n day 1. Th ey also ve ere d from
rel ati vely high e nergy a nd lack of tiredne ss o n
da y 1 to ma rked lack of energy a nd tire dn es s on
da y 2 which p ers isted somewhat to da y 5 (com-
pa red with alcohol u se rs) . Ra tings of a nxiety,
depre ssion an d agitatio n (a ll yielding
gro up 3da y inte ra ctio ns signi® cant at the
p,0.0 1 leve l) ea ch showed a p rogressi ve in -
cre as e over days fo r th e M D MA gro up , wh ile t he
alc oh ol g roup s ho wed le ss e xt rem e c hange s o ver
da ys w hich aga in follow ed a `U-shap ed curve.
Two scales revealed gro up 3da y interaction s at
th e 0.0 5 level, alth ough t hey s ho uld be inte r-
pre te d w ith ca ution given that the analy sis of 34
va ria ble s in t his stu dy wo ul d pro duce 1.7
sig ni ® can t res ults at 0.05 b y ch an ce. Irritability
rat ing s (p,0. 05) re ve ale d the same p att ern of
effe cts ov er day s; d ry mouth (p,0.0 5) h ad h igh
rat ing s by MD M A us ers on da y 1 . R a tin gs of
impaired co nc entratio n we re high est for alcohol
us ers o n d ay 1 , and h ighest for MDM A use rs o n
da y 2.
Discussion
Th e m ain re su lt of th is s tu dy ind ica te s th at u se
of M D M A at t he w ee ken d is ass oc iate d wi th a
low ering of m oo d m id-week . Score s on the Beck
De pre ssion I nv en tor y (B DI) , on several m oo d
rating scales (happy± sad; contented± discon-
ten te d; in te res ted ± bo red) a nd b od ily symptom s
sca le s (depress ed , an xious , ag ita ted ) all showed
ver y s ign i® cant gro u p d iffe ren ce s o ve r th e 5
da ys . O n all the se , M D M A use rs rat ed ele vat ed
mo od on day 1 which pro gr ess ively lo we red o ve r
su bs equ ent testi ng day s. I n c on trast, the alcohol
gro up sh ow ed a `U-sh ap ed’ c urve, with the l ow -
est point being d ay 2 , presum ab ly a han g-over
effe ct from day 1’ s co nsumption. On day 2, bo th
gro up s were bro ad ly simi lar in ra tin gs o n thes e
va ria bles , im pl yin g th at t he `d ay aft er’ effect s of
M DM A ( in clu din g la ck of s lee p) a re no t di ss imi-
lar in some res pe cts t o an alco hol hang-ov er.
Of partic ula r co ncern a re th e B DI sc ores of
M ood a nd c og niti v e ef fect s o f M D M A 827
Ta ble 2 . Gr oup mea ns (s tan da rd de viatio ns) o ver day s for sc ore s on th e Be ck Dep ress ion Inve nto ry an d in div idu al m oo d rat ings; AN O VA resu lts fo r eac h ra ting
AN OV A
MD M A Al co hol
Gr oup
Da y 1 Day 2 D ay 5 Da y 1 Da y 2 Da y 5 Gr oup Day 3d ay
BD I 3.5 ( 3.5 ) 8.7 ( 3.8 ) 11.8 ( 7.2 ) 6.4 ( 5.3 ) 8.3 ( 5.2 ) 6.9 ( 4.1 ) NS ** * ***
Mo od r atings (m m)
Dr owsy 19 .6 (2 7.1 ) 77.9 (14.5) 42.9 (23.8 ) 45.7 (27.0 ) 66.0 (1 4.1 ) 36 .8 (1 9.1 ) NS *** **
Ex cit ed 6 3.3 (37 .6) 14 .9 (9.4) 3 8. 9 (14 .8) 5 6. 8 (26 .3) 30.4 (15.1 ) 36.6 (1 4.9 ) NS *** NS
Feeble 17 .9 (1 6.4 ) 74.5 (15.0) 35.7 (16.6 ) 37.2 (17.7 ) 58.0 (9 .7) 38.8 (1 8.2 ) NS *** **
Cl ear -he ad ed 65 .1 (3 3.2 ) 24.1 (16.1) 58.1 (26.5 ) 34.2 (13.3 ) 37.3 (1 1.1 ) 63 .0 (1 6.2 ) NS *** **
Cl um sy 41 .4 (2 6.4 ) 67.6 (20.1) 35.6 (23.6 ) 62. 8 (12.6 ) 51.7 (1 5.2 ) 40 .0 (1 7.0 ) NS ** *
En erg etic 88 .3 (1 1.8 ) 17.8 (11.7) 46.8 (24.7 ) 61.0 (24.7 ) 31.8 (1 9.8 ) 49 .2 (1 4.8 ) NS *** **
Di sco ntente d 9 .4 ( 9.1 ) 3 8. 3 (24.0) 5 9. 4 (23 .3) 3 5. 4 (18 .5) 44.4 (19.5 ) 42 .5 (1 8.5 ) NS *** * **
Tr anq uil 75 .8 (1 5.7 ) 65.9 (24.5) 38.8 (19.1 ) 52.4 (12.6 ) 45.1 (1 7.9 ) 48 .2 (1 1.4 ) *** ** * *
Qu ick -w itted 51 .9 (3 1.6 ) 24.4 (16.6) 54.1 (21.9 ) 46.4 (22.8 ) 40.5 (1 9.7 ) 61 .3 (1 9.8 ) NS *** NS
Relax ed 71 .6 (1 5.2 ) 65.3 (24.6) 43.8 (30.3 ) 58.8 (22.6 ) 44.7 (2 0.9 ) 49 .4 (2 0.0 ) NS * N S
Dr eam y 44. 5 (37.3) 8 2. 8 (13 .1) 42 .6 (2 5.0 ) 49 .6 (2 2.3 ) 58 .2 (1 5.2) 38 .4 (17. 5) N S ** * N S
Pro ® ci en t 60 .8 (2 8.3 ) 35.8 (16.5) 65.6 (20.8 ) 48.8 (19.9 ) 49.8 (1 3.5 ) 64 .7 (2 0.3 ) NS *** *
Sad 7.0 (9. 9) 33. 5 (20.7 ) 5 4. 6 (27 .7) 2 6. 9 (21 .8) 41.6 (1 8.5 ) 35 .1 (1 6.9 ) NS *** * **
Am icable 82.8 ( 14. 5) 67. 4 (18 .7) 50 .5 (2 8.7 ) 60 .8 (2 5.1 ) 58 .2 (2 2.2) 60 .0 (14. 6) N S * *
Bo red 14 .4 (1 4.9 ) 49.6 (19.5) 62.8 (25.1 ) 41.9 (28.7 ) 55.9 (2 1.6 ) 39 .4 (1 0.7 ) NS *** * **
Gr ega rio us 68 .1 (1 9.3 ) 37.2 (18.4) 47.4 (22.8 ) 66.7 (18.8 ) 46.4 (1 8.3 ) 55 .5 (1 1.6 ) NS *** NS
***p,0 .00 1; ** p,0.0 1; * p,0. 05; N S n ot signi ® c ant.
828 H . V . C ur ra n & R. A . T ra vill
Ta bl e 3. G rou p m ean s (stand ar d deviat ion s) over d ays f or bo dily sym ptom s ra tin gs; A N OV A re su lts for each r atin g
AN O VA
M DM A Al co ho l
Gr oup
Da y 1 Day 2 Da y 5 Day 1 Da y 2 Day 5 G ro up Da y 3da y
Restle ssn es s 44.4 (3 2.1 ) 52.9 ( 28. 4) 58. 7 (17 .9) 37.8 (2 4.7) 58 .8 (14.7) 38.8 ( 16.8) N S N S NS
Irritab ilit y 17.6 ( 14 .1) 56. 0 (21 .1) 63 .6 (1 7.6) 33 .7 (2 5.7 ) 55 .7 (20.0) 44.1 (18.3) N S *** *
Physic al t iredne ss 15 .1 (1 8.7 ) 78.9 ( 11. 7) 60. 0 (21.3 ) 41. 9 (23.1) 64.5 (5 .9 ) 46 .1 (23 .1 ) NS *** * **
Lack of energ y 10. 6 (9 .7 ) 8 2.2 ( 11.4) 68.6 (1 5.1 ) 38.8 (22.5 ) 65.8 (8 .5 ) 48 .7 (23 .8 ) NS *** * **
Im pai red concen tra tion 47.3 ( 29 .9) 74. 2 (9.3) 62.1 (2 4.0 ) 67.3 (9 .5) 60.3 (1 6.2 ) 50 .3 (2 5.5 ) NS NS *
Heada ch e 18. 3 (18 .5 ) 5 8.3 ( 24.3) 37.6 (3 6.0 ) 21.8 (1 7.1 ) 50 .2 (3 1.7 ) 25 .8 (2 2.4 ) NS *** NS
Di f® cu lty b reath ing 3 3.7 ( 23 .2) 29. 7 (25.0) 19.8 ( 25. 2) 16.3 (17. 3) 24.0 ( 26 .4) 1 6.3 ( 15 .6) N S N S NS
Dr y m out h 73.2 ( 27 .3) 50. 1 (26.0) 23.8 (31. 0) 34.8 (21. 9) 43.8 ( 28 .6) 1 8.7 ( 22 .5) * *** *
Nausea 31. 1 (20 .5 ) 30.3 (26. 1) 9.3 (9. 2) 1 6.0 ( 14. 0) 3 0.7 ( 29 .1) 1 3.5 ( 15 .2) N S ** NS
Anxie ty 20. 8 (15 .6 ) 34.7 (23. 5) 52. 2 (21 .2) 18.7 (1 6.0 ) 40 .9 (2 1.4 ) 26 .9 (1 8.7) NS ** * **
Sweat ing 73. 6 (30 .7 ) 18.6 (15. 2) 8.6 (12 .0) 2 1.8 (21 .3) 33. 9 (22 .3 ) 14 .8 (18 .5 ) * * ** * **
Blu rre d visio n 55. 8 (28 .2 ) 21.3 (21.2) 12.4 (20 .5) 29.1 (2 3.9 ) 18 .5 (1 8.0 ) 8.8 ( 13 .4) * ** * N S
De pre ssi on 13 .3 (1 1.0 ) 45.2 ( 23. 1) 56. 3 (24 .4) 17. 4 (16 .5) 34 .7 (2 5.5 ) 20 .7 (1 3.6 ) * *** **
Ag itat ion 20.7 ( 20.7) 49. 1 (15 .6) 60 .8 (2 1.1 ) 30 .5 (2 7.1 ) 44 .5 (1 8.4 ) 24 .5 (15.4) * * * * *
***p,0.00 1; * *p,0 .01 ; *p,0 .05 ; NS not signi® can t.
M oo d and co gni tiv e eff ec ts o f MD M A 829
MDM A u se rs wh ich ind icate that some part ici -
pa nts are within the m ild to m od erate c lin ica l
ran ge for d ep res sio n. T he BD I incl ud es s ev era l
so ma tic item s referrin g to changes in s lee pi ng/
ea ting patterns. M D MA is k no wn to a ffect s leep
(A llen et a l., 1 993) and s ub ject iv e rep or ts of
decreased a pp eti te ar e co mmo n (Solowij et al.,
19 92; Liester et al., 1992). T o ex plore w he th er
hig h scores o n th ese s om at ic item s mi gh t ha ve
co ntributed to g roup d iffe ren ces in depression,
BD I s co res w ith th ese items o m itt ed were re-
an alyse d. H ow ev er, the p at ter n of sc ore s over
da ys and the s igni® cance o f the gro up 3da ys
in ter act ion (p,0.0 01) re ma ined. (Grou p m ea ns
for d ay s 1, 2 and 5, respecti ve ly, w er e: M D M A
2.2 5; 6 .91 ; 9.9 2; A LCO HOL 5.08; 6.83; 5.49).
T hus s om at ic effe cts o f MD M A we re no t ma in
co ntributory fa ctors t o group differenc es in de-
pre ss ion score s. T his also acco rds wi th t he re -
su lts o n v is ua l an alogue s cales. Our resu lt s are
co nsist ent w it h anecdo tal rep orts that MDM A
ca n lead to depression du rin g th e week afte r it is
ta ken (Barnes, 1988 ; S au nd ers , 19 95).
Lo w m ood d ay s after M DMA is ta ke n m ay
re¯ e ct s ero tonergic d ep let ion w hich m ight be
tem p orary foll ow ing acu te e levat ion of s ero tonin
in duced b y M DM A . If th is is the ca se, one
would ex pec t m oo d to lift over a longer time
co urs e. I f M DM A is se rot one rg ica lly n eu ro tox ic,
co mp lete re co very o f m oo d m ay n ot oc cur. It
co uld also be argued th at th e link b etwee n d e-
pre ss ion and MD M A m ay not b e a dire ct c on se -
qu en ce o f neurochem ical c ha ng es. T h e ap pa ren t
`low ’ exp er ien ce d in th e day s afte r M DM A u se
could be a psychological consequence of the
ac ut e `hig h’ follow in g M DMA. A s one M D MA
us er p ut it:
By dancing a ll n ight on E, a fee lin g o f to tal
bli ss an d utter ful® lm en t is achieved, a nd o f
cours e th e d ownside to t hi s is that no th ing else
bea ts that f eel ing , thus rea lit y can seem boring
(qu ot ed in Sa un de rs, 1995).
Th e present `® e ld s tud y has cl ear lim ita tions
co mp ared w ith a do ub le- bli nd, con tro lled labo -
rat or y st udy. N eit he r ex perim en ter no r pa rtici-
pa nts ha d objective con ® rm ation o f what dru gs
or dosages w er e actu al ly taken by th e M D MA
group. Tablets sold as MDM A can contain
MDA ( 3,4 me th yle nedio xy-amphet am ine),
M DE A ( `Ev e’ -3 ,4 m et hy len edi oxy eth yla m-
ph eta mi ne ), o r various m ixtures o f a ra nge o f
co mp ou nd s (e.g. ampheta mine, ketam in e, L SD ,
caf fein e, ep he drine). It w as b ey on d th e sc op e of
the present s tud y to att em pt b io ch emi ca l as say s:
req uests t o t ak e bl oo d or o th er bod ily ¯ uids m ay
ha ve m itiga ted again st p eople v olunt ee ring for
the s tudy as wel l as pr es enting health/sa fet y
pro bl em s fo r th e in ves tig ato r in a clu b s etting. It
co uld b e a rgued t ha t a fu rt he r lim itation of t he
pre se nt s tud y w as the c on joint u se o f alcohol
rep or ted by s om e o f th e M DM A us ers o n d ay 1 .
Ho we ve r, this was a t lo w dose s, w ith th e
M DM A gr ou p con su mi ng les s tha n 17% o f the
av era ge d ose repo rted by the alc oh ol grou p.
Although w e cannot be sure th at t he table ts
tak en b y t he M DM A g ro up co nt ain ed p ure
M DM A , t he pro® l e o f m oo d e ffec ts rep ort ed on
the night acc ords w ith previous ® ndin gs from
stu dies o f a cute e ffec ts o f kno wn dos es o f p ure
M DM A carr ied ou t be for e go ve rn me nta l res tr ic-
tio ns ( Do w nin g, 1 98 6; G re er & Ta lb ot, 1 98 6).
Th is p rovid es some ev idenc e th at the p artici-
pa nt s in th e p res en t st ud y h ad tak en M DM A .
Fu rth er, our ® nd in gs a lso acco rd with m ore re-
cen t re tro spect ive stu dies wh ich c ou ld n ot
co n® rm t ha t M D M A wa s a ct ua lly ta ken ( Per-
ou tka e t al ., 19 88; So lowij e t al., 1992; Leist er et
al. , 19 92 ). T he p ro ® le of p hy sic al side-effects
ob ta ined in this st udy, in clu di ng h ig h le vel s of
en erg y, s eve re d ry m outh an d swea ting, a lso
acc or ds w ith rep orts in t ho se studies .
Cogn iti ve ef fect s were sa mp led by re la tiv ely
few tes ts, and fu tu re stud ies ma y ex plore a m ore
co mp rehen siv e ra ng e o f co gnitiv e fu nctio n. T he
pro se recall ta sk ( im mediate an d d elayed) w as
cho sen o n t he b as is o f ® ndin gs b y K rystal &
Pri ce (1992) im plyin g th at p erforma nc e on both
imme diate a nd de lay ed a sp ec ts of this task
sh ow ed s om e di sru pt ion in ch ron ic M D M A
us ers . T he p res en t st ud y fo un d th at M D M A
us ers g en era lly p erform e d poorer t ha n a lco hol
us ers o n thi s task, an d bo th grou ps im p roved
ov er the 3 tes t da ys . A n on -s ign ca nt ( p,0.10)
ten dency em erged on delayed recal l re¯ ect ing
ma rg ina lly wo rs e perfo rm a nc e by MD M A use rs
on d ay 2. H ad the sa mp le s ize b ee n larger, t his
di ffere nce m ight have reached sign cance.
The s eri al se ve ns t ask wa s se lec ted pa rtly to
pro vi de a n in dex of a ttention /wo rk ing memory
an d pa rtly fol low in g Do wnin g et a l. (1986) w h o
rep orted a sma ll num be r of MDM A use rs having
pro bl em s ca rry in g out m athe ma tic al calc ula-
tio ns . MD M A us ers w ere im pa ire d on t his ta sk
(co mpared wi th a lco ho l us ers) on all 3 test ing
830 H . V. C urr an & R. A. Tr av ill
da ys a lthou gh imp airme nts we re m os t pro-
no un ced on da y 2. It is not clea r wh et her thi s is
a direc t d rug effect or wh eth er lack of sle ep,
rep or ted by m os t M DM A u se rs o n da y 2, a ls o
co ntributed to impairm en t. Imp aired atten tional
fun ct ion could i n tu rn a ffect perform ance on a
ran ge of t as ks, i nclud ing compre hension an d en-
co ding in the p rose r eca ll t as k. In de ed , it is
po ssible tha t ap pa ren t mem ory pr ob lem s link ed
to M DM A c ou ld be ex pl ain ed by t he co ntr ibu -
tio n of con ce nt rati on a nd link ed encoding
de® cits.
As f ar a s we are a wa re, the prese nt s tudy is the
® rst to investi gat e th e m oo d and c og nitive e ffec ts
of we ek en d M DM A u se in te rms o f bot h acu te
an d res idu al eff ect s ove r sub se que nt da ys . W e
are c urr en tly as se ssin g M D M A u se rs o ve r a
lo ng er ti me peri od . If t he m id -w eek lo w m oo d is
du e to a te mporary de pletio n in 5- HT , a s op -
po sed to 5- HT ne ur oto xicity, there w ou ld b e a
tim e course o ver w hic h moo d wo ul d lift.
In te rm s o f th e d ebate about the us e o f
MDM A as a n ad ju nc t to p sy choth era py, the
results of the present study would caution
ag ain st t he u se of a drug w hich in so me peop le
might co mp ou nd pro blems by ind uc ing a lo we r-
in g of mo od so me days after a t her ap y se ss io n.
The present ® ndings also add to the list of
ad verse c on se qu enc es o f M D MA u se, in that the
`hig h’ at the w ee ken d m ay le ad to a `low m id -
week and to atte ntional problems . T his may be
of p ar tic ular concern to th os e w ho se s tu di es or
job perf orm a nce may s uff er fr om imp aire d a tte n-
tio nal fun ct ion.
In summ ary, th e re su lt s of t his st ud y im ply
th at MD M A us e at the we ek en d is ass oc iate d
with s ub sequent lo w m ood m id -w eek and with
im pa ired at te ntional fu nc tio n. I t is n ot cle ar t o
what ext en t th is may re¯ ect a te mp orary sero-
to ne rgic dep le tio n, a m ore serio us s ero to nergic
neuroto xic ity or a psychologica l co ns equen ce of
th e acu te `high’ m ood in du ced by week en d
MDM A use.
Referen ce s
ALLEN R. P ., M CCANN, U. D. & R IC AU R T E , G . A.
(1993) Persistent effects of 3,4-m ethy lene-
dio xy me tha m ph eta mi ne (M DM A , `E cst as y’ ) o n
hum a n sleep , Sleep, 16, 560± 5 64.
BARNES, D . M. (198 8) Ne w d ata inte ns e s t he agony
ove r E cst asy , Sc ien ce, 2 39, 86 86 6.
BEC K , A. T . ( 197 8) T he Beck Depression In ventory
(BD I ) (The Psychological Corporation Harcourt
Bra ce Jov an ovitz In c. , US A).
BOND, A. J . & LADER , M . H . (1 974 ) T he us e o f
an alo gu e sc ale s in r at ing s ub jec tiv e feelings , British
Jo ur nal of M ed ica l P sy cho log y, 4 7, 21 2 18.
CUR RA N , H . V . & K OPELMAN, M . D . ( 199 6) Th e c og -
nit ive p syc hop ha rm aco lo gy of Al zhe im er’ s D ise ase ,
in: R. G . M . M ORRIS (Ed .) T he C ogn iti ve N eur ops y-
chology of A lzheimer’ s Disease, pp . 255 ± 277 (O xf or d,
Ox fo rd U niv er sity P re ss).
DOW N IN G , J. (1 986 ) T he psychologi ca l a nd ph ys iol ogi -
ca l eff ec ts o f M D MA on norm a l vo lu nt eers , Journal
of Psy cho acti v e D r ugs, 1 8, 3 35± 340.
ELKIN, I. (199 4) The NI MH tr ea tment o f d ep res sio n
co lla bor ati ve re sea rc h pr og ram m e: where we be ga n
an d w her e w e a re , in: B ER G IN , A. E. & GARFIELD, S.
L. ( Ed s) H an db oo k o f P sych ot her ap y a nd Beh avi ou r
Ch ang e, p p. 1 14± 119 (N ew Yo rk, Wi ley ).
FINN I G A N , F. & H AMMERSLEY, R. (1 992 ) Th e effects of
alc oh ol o n p erf or ma nce , in : SM I T H , A. & JONES, D.
M . (E d s) Han db oo k of H um a n Per for man ce , pp . 73±
126 (L on do n, A cad em ic P re ss).
GREE N , A . R. , CROSS, A . J. & G O OD W IN, G . M . (1 995 )
Re vie w o f th e p har ma co lo gy a nd c lin ica l ph arm -
ac ol ogy o f 3,4 -m et h yle ne d ioxy m eth am p het am in e
(M D M A o r `Ec sta sy ’ ), P sy cho pha rm aco log y, 11 9,
247 ± 260 .
GREE R , G . & TALB O T , P. (1986) Sub jec tive r epo rt s o f
the effe cts of M DM A in a cl ini ca l set tin g, J ournal of
Ps ych oa ctiv e Dru gs, 1 8, 3 19± 327.
KRYSTAL, J. H . & P RI C E, L . H. (1 992 ) Ch ro ni c M D M A
use : ef fects on mood and neuropsychological func-
tio n?, A merican J our na l of D ru g an d A lco ho l Ab use ,
18, 331± 341.
LIESTER, M . B. , G ROB, C . S., BRAVO, G. L. & W ALSH,
R. N . (1992 ) Phen om enology and se que lae o f 3 ,4-
me thy le ned io xy met ha mp het am in e us e, J our na l of
Ne rvo us a nd M en tal D is ord ers, 1 80, 34 35 2.
MCGUI RE, P . K ., C OPE, H. & F AHY, T. A. ( 199 4)
Di ve rsit y of psyc ho patho lo gy as so ciat ed w ith us e of
3,4 -m eth y le ne dio xy me th am ph et am in e ( `Ec sta sy ’ ),
Br itish J ou rna l of Psy chi atr y, 16 5, 391± 3 95.
PEROUTKA, S. J. (1987) Incidence of re cre atio na l u se of
3,4 -m eth y le ne dio xy me th am ph et am in e (M D M A
`Ec sta sy’ ) o n an un der gra dua te ca mp us, N ew
En gla nd Jou rna l of Med icin e, 317, 1542± 1543.
PEROUTKA, S . J., N E WM A N , H. & H ARRIS, H. (198 8)
Su bje ctive e ffe cts o f 3,4- me th ylenedi oxy me tha m -
phe ta mi ne in r ec rea tio na l use rs, Neur op sych ophar ma -
col og y, 1, 27 277.
RICAURTE, G. A ., M ARTELLO, A . L., KATZ, J. L. &
MARTELLO, M . B. (19 92) L astin g ef fects of ( 6)-3,4 -
me thy le ned iox ym eth am ph eta mi ne (M DM A ) on
cen tr al se ro to ner gic n eu ron s in n on hum an pr im ate s:
ne uro che m ica l ob serva tio ns, Journal of Pharmacology
and Experim ental Th erapeutics, 26 1, 616 ± 62 2.
SAUNDERS, N . (1 995 ) Ecstasy and the Dance C ulture
(Lo nd on , Neal’s Yard D esk to p Pu blishing).
SCHMIDT, C . J. (198 7) Neuroto xicity of the p syc he del ic
am ph eta mi ne m eth yl ene dioxyme tha mphe ta mi ne,
Jo urn al of Pha rm acolo gy and Ex perimental Thera-
peutics, 24 0, 1 ± 7 .
SHAPIRO, D. A ., B ARKHAM, N ., REE S, A ., H ARDY, G . E. ,
REYNOLDS, S . & S TARTUP, M . (1 994 ) E ff ect s of
tre atm e nt d ur ation and se ve rit y of d ep res sio n on the
eff ec tive ne ss o f c og nit ive/ be hav iou ra l an d ps ych o-
dy na mic /in ter per son al psych other apy, Journal of
Co nsu lti ng an d C lin ical P sy cho log y, 62 , 52 53 4.
M oo d and co gni tiv e eff ec ts o f MD M A 831
SOLOWIJ, N ., HALL, W . & LE E, N . (19 92) Re creati on al
MD M A us e in Sy dn ey: a pro ® l e of `Ecst as y’ use rs
an d the ir e xpe ri enc es w ith th e d ru g, Br itis h Jo ur nal o f
Add icti on , 87, 1161± 11 72.
STEELE, T . D., MCCANN, U . D . & R ICAURTE, G . A .
(199 4) 3 ,4-m et hy len edi ox yme tha mp het am in e
(M DM A , `Ec sta sy’ ): pha rm ac olo gy and t ox ico log y
in a nimals an d h um an s, A dd icti on , 89, 539 ± 551.
WILSON, B., C OCKBURN, J. & BADDELE Y, A. (19 85) T he
Riv er me a d Beh avi ou r al M em o ry T est ( Rea di ng , UK ,
Th am es V al ley T ex t Co .).
YAMAMOTO, B . & SPANOS, L. (1 988 ) T he acu te ef fec ts
of m et hyl en edi ox ym eth am ph eta mi ne o n do pamin e
rel ea se in the aw a ke- beh av ing rat, Eur op ean J our na l
of P har ma col og y, 148 , 195± 2 03.
... The presence of withdrawal syndrome and the suicide risk after MDMA has ceased to work is also a concern. However, it has been established that mid-week blues is mainly due to lack of sleep, excessive physical activity, reduced food intake, use of other psychoactive substances (Sessa, 2017;Curran, 1997). ...
... Obawy budzi także występowanie zespołu odstawiennego i ryzyko suicydalne po ustąpieniu działania MDMA. Ustalono jednak, ze zespół mid-week blues wynika przede wszystkim z braku snu, nadmiernej aktywności fizycznej, ograniczenia przyjmowania posiłków, używania innych substancji psychoaktywnych (Sessa, 2017;Curran, 1997). ...
Article
MDMA (3,4-methylenedioxymethamphetamine) is a psychoactive substance classified as a hallucinogen. MDMA acts in the brain through a variety of neurochemical mechanisms, reducing anxiety, giving a sense of oneness with other people, expanding empathy, sharpening the senses and intensifying the experience of emotions. Therefore, the use of the MDMA assisted psychotherapy is being considered in selected disorders, such as Posttraumatic Stress Disorder (PTSD), Social Anxiety Disorder (SAD) in people with Autism Spectrum Disorder (ASD), and in treatment of alcoholic addition. Although the recreational use of ecstasy may lead to numerous life-threatening side effects, data available in the literature suggest that psychoactive substances may be safely administered in clinical settings. This article aims to review current research on the MDMA assisted psychotherapy. The first part of the article concludes data on MDMA assisted psychotherapy from available clinical trials. The second one sums up hopes and fears associated with the administration of MDMA in clinical settings that were discussed in the current clinical discourse. It seems that further studies are needed to determine the long-term safety and effectiveness of MDMA assisted psychotherapy.
... Ecstasy (3,4-methylenedioxymethamphetamine -MDMA) is a common recreational drug and sought effects include euphoria and feelings of happiness (Curran & Travill, 1997) along with increased energy, musical appreciation and emotional closeness with others (Pascoe et al., 2022). Illicitly acquired MDMA can vary in appearance, with crystalline and tablet forms available (Pascoe et al., 2022). ...
Preprint
Full-text available
Background: Adverse drug reactions (ADRs) can occur due to ecstasy use, and the number of people dying due to drug-related deaths has increased in the past 10 years. Self-initiated harm reduction strategies could help prevent ADRs or decrease the incidence of life-threatening health consequences due to ecstasy use. Methods: A rapid scoping review was conducted using adapted JBI methodology. The objectives were to describe the strategies employed by ecstasy users to minimise harm, the sources of information they rely on, and to assess the content of user-oriented websites regarding detrimental effects and harm reduction practices. Five databases (CINAHL, EMBASE, Medline, PsycINFO, CENTRAL) were searched for English language records from database inception to August 2022. User-oriented websites were identified via the project’s stakeholder group and Google searches. Results: Twenty reports representing 19 studies (one RCT, nine quantitative descriptive studies and nine qualitative studies) were included. A wide variety of self-initiated harm reduction strategies were reported, including drug checking, dose control (including buying from trusted sources), seeking peer support (e.g., looking out for friends), hydration management and temperature regulation (e.g., monitoring water consumption, taking rest breaks, and avoiding alcohol), avoiding polydrug use, and pre- / post-loading. Information on ecstasy’s effects and/or harm reduction practices is obtained from a variety of sources including friends, nightclubs, drug leaflets, and user-oriented websites. Fourteen websites providing ecstasy-specific harm reduction information were also identified and quality assessed. However, only two webpages provided citations to the evidence used for the content. Conclusions: The provision and quality assessment of ecstasy harm reduction advice from various sources has been collectively analysed for the first time. We hope and anticipate that use of this rapid scoping review will facilitate more comprehensive, evidence-based harm reduction messaging, reducing the likelihood of future ADRs and life-threatening health consequences related to ecstasy use.
... While score weights for the remaining substances indicate either a risk increase (i.e., tobacco, barbiturates, and cocaine), a risk decrease (i.e., heroine) or no association at all (i.e., marijuana, cocaine, and codeine), none of the selection rates were larger than 81%. The positive weight of amphetamines is consistent with work on recreational amphetamine use and selfreports of depressive symptoms (Curran & Travill, 1997;Gerra et al., 2000;MacInnes et al., 2001). The negative weight of alcohol has to be interpreted with caution: Especially, a protective effect of alcohol is highly unlikely (McCambridge et al., 2011). ...
Article
Full-text available
Regression models with interaction terms are common models for moderating relationships. When effects of several predictors from one group-for example, genetic variables-are potentially moderated by several predictors from another-for example, environmental variables-many interaction terms result. This complicates model interpretation, especially when coefficient signs point in different directions. By first forming a score for each group of predictors, the interaction model's dimension is severely reduced. The hierarchical score model is an elegant one-step approach: Score weights and regression model coefficients are estimated simultaneously by an alternating optimization (AO) algorithm. Especially in high dimensional settings, scores remain an effective technique to reduce interaction model dimension, and we propose regularization to ensure sparsity and interpretability of the score weights. A nontrivial extension of the original AO algorithm is presented, which adds a lasso penalty, resulting in the alternating lasso optimization algorithm (ALOA). The hierarchical score model with ALOA is an interpretable statistical learning technique for moderation in potentially high dimensional applications, and encompasses generalized linear models for the main interaction model. In addition to the lasso regularization, a screening procedure called regularization and residualization (RR) is proposed to avoid spurious interactions. ALOA tuning parameter choice and the RR screening procedure are investigated by simulations, and two illustrative applications to depression risk are provided. (PsycInfo Database Record (c) 2022 APA, all rights reserved).
... The potential for post-acute cognitive and affective impairment has been well-documented among recreational MDMA users (e.g. Curran and Travill, 1997;Verheyden et al., 2003). Acute post-MDMA lowered affect, occurring as the drug effects wear off, is often referred to colloquially as a 'come down'. ...
Article
Background Incorporating 3,4-methylenedioxymethamphetamine (MDMA) as an adjunct to psychotherapy has shown promise in recent years for treating various mental health conditions, particularly those involving trauma. However, concerns about declines in mood and cognition during the days following dosing, also known as ‘Blue Mondays’, have been raised as limitations to its clinical use. Although these changes have been well-documented among recreational users, there are critical confounds to these reports that limit generalizability to clinically administered MDMA. Aims Here, we aimed to evaluate the evidence basis for the negative side effects associated with MDMA as well as inform our understanding of the drug’s post-acute effects in a clinical context with an open-label study. Methods The current open-label study examined MDMA therapy for alcohol use disorder (AUD; N = 14) and measured mood, sleep quality, illicit MDMA consumption and anecdotal reports after the acute drug effects had worn off. Results Participants maintained a positive mood during the week following drug administration in a clinical context. Relative to baseline, self-reported sleep quality improved at the 3- and 6-month follow-ups. Finally, no participants reported using or desiring to use illicit MDMA, and the anecdotal reports indicated that they perceived the treatment favourably. Conclusion The results support the overall safety and tolerability of clinically administered MDMA and, importantly, suggest that the ‘come downs’ previously associated with the substance may be explained by confounds in research relating to the illicit sourcing of the drug and specific environmental setting for recreational consumption.
... MDMA has potent sympathomimetic and serotonergic effects. The serotonergic actions of MDMA are the presumed mechanism of euphoria and feeling of happiness among its users [1]. MDMA has been associated with acute and chronic toxicities. ...
Article
Full-text available
3,4-Methylenedioxymethamphetamine, MDMA, or "ecstasy", is a trending recreational drug used by the young crowd for obtaining "euphoria." Over the past few years, there have been multiple reports of teenagers committing suicide and suddenly dying post ingesting MDMA. Compared to other illicit drugs such as heroin, hash and cocaine, ecstasy is relatively new hence the popularity. There are multiple toxicities associated with MDMA, including but not limited to seizures, depression, liver failure, or thrombosis. However, in this report, we will focus on hyponatremia and one of the most feared complications of such electrolyte disturbance: seizures. The rapid reversal of the hyponatremia with hypertonic saline in such acute setting is key to reduce risk of cerebral swelling. We report a case of a young female with no past medical history who presented to emergency department post ecstasy use with tonic-clonic seizure and hyponatremia.
... ,2001(Cottler et al.,. , , 2009Yen & Hsu, 2007), (4) tolerance to the positive effects (Kirkpatrick et al., 2012;Parrott, 2005;Peroutka et al., 1988;Yen & Hsu, 2007) and (5) development of withdrawal symptoms (Curran & Travill, 1997;McKetin et al., 2014;Peroutka et al., 1988). ...
Article
Full-text available
Methylenedioxymethamphetamine (MDMA) is an amphetamine analogue that preferentially stimulates the release of serotonin (5HT) and results in relatively small increases in synaptic dopamine (DA). The ratio of drug‐stimulated increases in synaptic DA, relative to 5HT, predicts the abuse liability; drugs with higher DA:5HT ratios are more likely to be abused. Nonetheless, MDMA is a drug that is misused. Clinical and preclinical studies have suggested that repeated MDMA exposure produces neuroadaptive responses in both 5HT and DA neurotransmission that might explain the development and maintenance of MDMA self‐administration in some laboratory animals and the development of a substance use disorder in some humans. In this paper, we describe the research that has demonstrated an inhibitory effect of 5HT on the acquisition of MDMA self‐administration and the critical role of DA in the maintenance of MDMA self‐administration in laboratory animals. We then describe the circuitry and 5HT receptors that are positioned to modulate DA activity and review the limited research on the effects of MDMA exposure on these receptor mechanisms. image
... In addition to acute intoxication, the risks associated with drug use in the nightlife scene may include violence, accidents, driving or being driven by someone under the influence, risky or unwanted sex, poor sleep, emergency medical treatment and, in extreme cases, death (Calafat et al., 2010;Calafat et al., 2011;Chinet, Stéphan, Zobel, & Halfon, 2007;Gripenberg-Abdon et al., 2012;Montgomery, Fisk, Wareing, & Murphy, 2007;Nordfjaern et al., 2016;Taurah, Chandler, & Sanders, 2014). A number of psychological problems have also been observed in the days after drug use, including impaired cognitive functioning, anxiety and depressed mood (Chinet et al., 2007;Curran & Travill, 1997;Montgomery et al., 2007;Parrott & Lasky, 1998;Taurah et al., 2014). ...
Conference Paper
The use of alcohol and illicit drugs has long been a feature in the nightlife scene. However, there is a current paucity of research on contemporary patterns of drug use in European nightlife populations. Furthermore, there have been considerable developments in the European drug market, potentially placing people at elevated risk of harm. In Chapter 1, I provide an overview of this key gap in the literature and introduce the ALAMA-Nightlife project, a multi-country collaboration designed to address this. In Chapter 2, I demonstrate that the internet can be successfully used to recruit a sample of young European adults engaging with the nightlife scene, by showing an online sample to be broadly representative in terms of drug use, nightlife engagement and demographics as an offline sample recruited at nightclubs and festivals. The cross-sectional profiles of drug use are examined in Chapter 3, with Latent Class Analysis revealing six distinct subgroups indicating substantial heterogeneity in drug use patterns. Furthermore, increasing levels of polydrug use were associated with higher scores on indices of problematic alcohol and drug use. In Chapter 4, I examined the relationship between harm reduction and polydrug use, and identified five discrete patterns of personal protective strategies that differed in levels of polydrug use. Extensive endorsement of harm reduction behaviours was also associated with more positive and fewer negative consequences following drug use. Longitudinal trajectories of drug use in the European nightlife scene are assessed in Chapter 5, with findings suggesting considerable stability over the course of 12 months. Amongst the small percentage whose use did change at follow-up, both an increase and decrease were associated with lower perceptions of risk, while increasing or decreasing the number of electronic dance music events attended was associated with a corresponding change in drug use. In Chapter 6, I summarise these findings, discuss their implications and how they address current gaps in the evidence while considering their limitations, and suggest areas for future research on drug use in the European nightlife scene.
Preprint
Full-text available
Background: Adverse drug reactions (ADRs) can occur due to ecstasy use, and the number of people dying due to drug-related deaths has increased in the past 10 years. Harm reduction strategies could help prevent ADRs or decrease the incidence of life-threatening health consequences due to ecstasy use. However, no reviews have explored the breadth of evidence available on ecstasy harm reduction strategies. Methods: A rapid scoping review was conducted using adapted JBI methodology to identify the prevalence and nature of harm reduction strategies that ecstasy users employ in recreational settings, with both peer-reviewed research and user-oriented drug information websites explored. Five databases (CINAHL, EMBASE, Medline, PsycINFO, CENTRAL) were searched for English language records from database inception to August 2022. User-oriented websites were identified via the project’s stakeholder group and Google searches. Results: Twenty reports representing 19 studies (one randomised control trial, nine quantitative descriptive studies and nine qualitative studies) were included. A wide variety of harm reduction strategies were reported, including drug-specific strategies (for example, limiting the amount of ecstasy consumed, buying from trusted sources, drug checking (pill testing)); behavioural strategies (for example, monitoring fluid (water) consumption, taking a rest break to regulate temperature, avoiding alcohol and mixing with other drugs; preloading and post-loading); and peer-related strategies (for example not using alone, looking out for friends). Ecstasy users obtain information on ecstasy’s effects and/or harm reduction practices from a variety of sources including friends, nightclubs, TV news, drug leaflets, music magazines and user-oriented information websites. Fourteen user-oriented websites providing ecstasy-specific harm reduction information were identified, and strategies focused on dosage and frequency of use, interaction with other substances and prevention of health consequences, such as heatstroke, or dehydration among others. However, only two webpages provided citations to the evidence used for the content. Conclusions: While numerous harm reduction strategies exist, employing them can depend on the users’ overall goal/s which might also encompass avoiding comedown or increasing their high. Moreover, users’ previous experience can influence how and when they adhere to harm reduction. More efficient ways of communicating harms and harm reduction strategies might be needed.
Article
Full-text available
A total of 117 depressed clients, stratified for severity, completed 8 or 16 sessions of manualized treatment, either cognitive–behavioral psychotherapy (CB) or psychodynamic–interpersonal psychotherapy (PI). Each of 5 clinician-investigators treated clients in all 4 treatment conditions. On most measures, CB and PI were equally effective, irrespective of the severity of depression or the duration of treatment. However, there was evidence of some advantage to CB on the Beck Depression Inventory (Beck, Ward, Mendelson, Mock, & Erbaugh, 1961). There was no evidence that CB’s effects were more rapid than those of PI, nor did the effects of each treatment method vary according to the severity of depression. There was no overall advantage to 16-session treatment over 8-session treatment. However, those presenting with relatively severe depression improved substantially more after 16 than after 8 sessions.
Chapter
Alzheimer's disease can be thought of as a multi-faceted neuropsychological disorder, with diverse impairments in cognitive abilities, such as attention, memory, language and executive functioning. Over the last decade cognitive neuropsychology has provided a far richer understanding of these impairments, and this book describes these advances, placing them in their clinical context. The first section deals with background theoretical and clinical issues, such as the extent to which Alzheimer's disease can be considered as a single entity or whether it is more fruitful to explore the neuropsychology of individual patients. It considers the diagnostic aspects of Alzheimer's disease, the natural history of the disease, how it progresses over time and the characteristics of the prodromal phase. A second section, the core of the book, covers major cognitive functions and delineates how impairments can be differentiated from each other. A third portion integrates what is known about cognitive decline with the underlying neurobiological basis, including pathological structural brain abnormality and neuropharmacological changes. The final section explores the clinical implications of the research with an overview of the neuropsychological assessment of this disease, cognitive approaches to management, and neurobiological treatment. As an introduction to this field, The Cognitive Neuropsychology of Alzheimer's Disease brings together the opinion of leading researchers in a book that will provide a useful source of information for neurologists, neuropsychologists, psychiatrists and neuroscientists who wish to broaden their knowledge concerning this debilitating condition.
Article
the primary purpose of the TDCRP [Treatment of Depression Collaborative Research Program] was to test the feasibility and value of carrying out multisite collaborative outcome studies in the area of psychotherapy / there were two major goals of the [program]: (1) to test the feasibility and usefulness of the collaborative clinical trial model in the area of psychotherapy research and (2) within the context of this model, to test the effectiveness of two brief psychotherapies for the treatment of outpatient depression [cognitive behavior therapy and interpersonal therapy] (PsycINFO Database Record (c) 2012 APA, all rights reserved)
Article
considers the acute effects of alcohol on human performance, concentrating on the literature of 1980–1991 / its orientation is cognitive methodological problems / models of the psychopharmacology of alcohol / mediators of the alcohol–performance relationship (PsycINFO Database Record (c) 2012 APA, all rights reserved)
Article
Administered 16 visual analog scales to 8 normal Ss to test the validity of the scales in measuring drug effects; Ss received 150 mg of butobarbitone sodium, 15 and 30 mg of flurazepam, and a placebo. Results indicate that (a) there were no significant effects on Factor 1 (Alertness), but there was a tendency for Ss to rate themselves as more alert after placebo; (b) there was a significant Drug * Times interaction effect on Factor 2 (Contentedness); and (c) Factor 3 (Calmness) also showed a significant Drug * Times interaction effect which was caused by the anti-anxiety effect of flurazepam. (15 ref) (PsycINFO Database Record (c) 2004 APA, all rights reserved)
Article
'Ecstasy' (3,4-methylenedioxymethamphetamine or MDMA) is a recreational drug that is gaining popularity world wide. There is a paucity of research regarding the ways in which Ecstasy is used and the nature of its effects. A 'snowball' peer network technique was used to recruit 100 users who completed anonymous questionnaires. The research revealed that Ecstasy is primarily used by infrequent recreational drug users for 'fun' at dance parties and social gatherings. The primary reported effects of Ecstasy were a 'positive mood state' and feelings of intimacy and closeness to others. The secondary effects of Ecstasy were the stimulant effects of energy and activation, and the psychedelic effects of insight and perceptual and sensual enhancement. Ecstasy was reported to share the properties of both amphetamines and hallucinogens in the nature of its side effects and residual effects which were no more severe than those of the latter two classes of drug. It appeared Ecstasy was not conducive to regular and frequent use, because tolerance was reported to develop to the positive effects of Ecstasy, while negative effects increased with use. Although few problems associated with the recreational use of Ecstasy have surfaced to date, animal research has shown it to be neurotoxic to serotonergic nerve terminals. Caution must be observed until further research can determine the level of hazard in humans.
Article
3,4-Methylenedioxymethamphetamine (MDMA) has been at the center of a debate over its potential benefits as an adjunct to psychotherapy versus its capability for neurotoxic effects and is currently classified as a Schedule 1 drug by the Drug Enforcement Administration (DEA). However, as yet, there is very little methodological data on the subjective experience of the MDMA-induced state or its psychological and behavioral sequelae. The present study was, therefore, designed to obtain this kind of information. Twenty psychiatrists who had taken MDMA previously were evaluated using a semistructured interview. Subjective experience of the actual MDMA-induced state, as well as both short-term (less than 1 week) and relatively longer term (greater than 1 week) sequelae, were examined retrospectively. Side effects, insight gained, pleasure, and intensity of the MDMA experience were evaluated as were the influence of set and setting at the time the MDMA was taken and the dosage utilized. Finally, the authors discuss methodological problems and limitations of a study of this type.
Article
3,4-Methylenedioxymethamphetamine (MDMA; "ecstasy") is a selective serotonin (5-HT) neurotoxin in animals. There is now preliminary evidence in humans of 5-HT deficits associated with extensive use of MDMA. In order to begin to describe the cognitive and mood effects of chronic MDMA use, nine individuals with extensive MDMA use histories were studied. Despite the absence of memory deficits on clinical examination, a pattern of mild-to-moderate impairment was observed on both the Initial and Delayed Paragraph Tests of the Wechsler Memory Scale; eight of the subjects had at least mild impairment on at least one test in the neuropsychological battery. Despite previously reported suggestive evidence of 5-HT deficit in this group, none reported depressed mood or met clinical criteria for an affective disorder at the time of testing. These preliminary findings raise concern about possible detrimental effects of MDMA use on neuropsychological function for future systematic study and they highlight important issues regarding the effects of 5-HT deficits on cognitive function and mood regulation.